Bayer Cares Foundation Promotes Sustainable Growth by Supporting Social Impact Pioneers with Grants Totaling EUR 1 Million

BayerGrants4Impact (G4I), a new energizer program launched by Bayer Cares Foundation, is providing targeted support to social impact pioneers and start-ups in the fields of healthcare and nutrition. The aim of the program is to give selected change-makers around the world new opportunities to grow and transform great ideas into powerful impact solutions that help to improve the lives of millions. In batch periods of two years five carefully selected projects are being granted a total of EUR 1 million to help scale their ideas to the next level of impact. Each project receives EUR 150,000 in cash contributions as well as additional in-kind benefits (e.g. training, mentoring, coaching and PR or visibility boosts) worth EUR 50,000 in all.

"Grants4Impact is to be a kind of incubator for visionary social pioneers working on solutions to the major challenges in the healthcare and nutrition fields," explains Thimo V. Schmitt-Lord, CEO, Bayer Foundations. "Besides gaining access to more funding, these young entrepreneurs will be gaining valuable know-how through the close cooperation with Bayer. Together we want to unleash the scale-up potential of their projects to help millions of disadvantaged people around the world enjoy a better quality of life."

The five projects to be supported in the first round of Grants4Impact awards are SANI SOLAR, a solar-powered maintenance-free sanitation project developed in Germany and being piloted in Brazil; COOLAR, an electricity-free cooling system for drugs and food developed in Germany and being piloted in Kenya; SafetyNet, a smart nets for selective fishery project developed in the UK and being piloted in Indonesia; BISA M-Health, a telemed service developed in Ghana and being piloted in Senegal; and iBreast Exam, a handheld breast cancer screening device developed in the USA and being piloted in Brazil.

iBreast Exam - facilitating mass screenings for breast cancer

Breast cancer is the most common invasive cancer in women worldwide. Survival rates differ greatly, depending on the stage at which a tumor is detected. That is why early screening is so important. In many low- and middle-income regions of the world women are generally diagnosed at late stages since mammograms are not available. As a result, around 70% of all breast cancer deaths occur in such regions. iBreast Exam, a revolutionary handheld breast cancer screening device, is capable of changing this sad state of affairs. Developed in the USA by Mihir Shah, iBreast Exam is radiation-free, painless, and being deployed in a pilot project in a remote area of Brazil. In cooperation with DASA and a network of selected clinics, some 10,000 women with no access to regular screening will thus be given the possibility of having a tumor detected at an earlier stage than otherwise possible - and will thus enjoy a higher chance of survival.

All five projects from the first Grants4Impact round were nominated for the Aspirin Social Innovation Awards 2017-18. Bayer Cares Foundation presents these awards to innovative concepts that are helping to close gaps in the healthcare and nutritional fields and have the potential to create sustainable systemic changes. 33 initiatives or social pioneers have been awarded a total of EUR 235,000 since the program was introduced in 2010.

For further information, please visit:
http://www.bayer-foundations.com

Bayer Cares Foundation

As the social impact foundation of the innovation company Bayer, the Bayer Cares Foundation sees itself as initiator, promoter and partner for innovation at the interface between academia, industry and civil society. The programs are focused on people - their commitment to societal progress, their wealth of ideas in fulfilling social challenges, and those that arise in times of emergency. The foundation's funding activities are a central element of Bayer's global corporate societal engagement (CSE) of around EUR 49 million annually - with the focus on promoting frontier science and social innovations connected to the UN's Global Development Goals of Zero Hunger and Health and Well-Being.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of 35.0 billion euros. Capital expenditures amounted to 2.4 billion euros, R&D expenses to 4.5 billion euros.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...